ESMO 2021 | Gastroesophageal carcinoma with HER2 gene amplification
Daniel Catenacci
• 27 Aug 2021
Daniel V. Catenacci, MD, of the University of Chicago Medical Center, Chicago, IL, discusses an abstract presented at the European Society for Medical Oncology Congress (ESMO) 2021 Meeting investigating the incidence of gastroesophageal carcinoma with HER2 gene amplification. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr Catenacci reports disclosures with Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Novartis, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Pierian, Silverback Therapeutics, Servier, Blueprint Medicines, Arcus BiosciencesTempus, Guardant Health, Archer & Natera.
